Brinzolamide

• Description:

  Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research[1][2].

• Product Name Alternative:

  AL-4862

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Carbonic Anhydrase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Neurological Disease; Others; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Brinzolamide.html

• Purity:

  99.91

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=S(C(S1)=CC2=C1S(N(CCCOC)C[C@@H]2NCC)(=O)=O)(N)=O

• Molecular Formula:

  C12H21N3O5S3

• Molecular Weight:

  383.51

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1] Vatsala Naageshwaran, et al. Comprehensive Ocular and Systemic Pharmacokinetics of Brinzolamide in Rabbits After Intracameral, Topical, and Intravenous Administration. J Pharm Sci. 2021 Jan;110 (1) :529-535.|[2] Sara M.Smith, et al. Tolerability, pharmacokinetics, and pharmacodynamics of a brinzolamide episcleral sustained release implant in normotensive New Zealand white rabbits, Journal of Drug Delivery Science and Technology, Volume 61,2021,102123, ISSN 1773-2247

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  CA II

• CAS Number:

  [138890-62-7]